These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2120813)

  • 1. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation.
    Welter HF; Illner WD; Schleibner S; Abendroth D; Hancke E; Groh J; Land W
    Transplant Proc; 1990 Oct; 22(5):2272. PubMed ID: 2120813
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic monitoring in OKT3-treated kidney graft recipients.
    Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
    Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3).
    Prieto C; Rodriguez-Paternina E; Andrés A; Morales JM; Farias J; Montoyo C; Regueiro JR; Rodicio JL
    Transplant Proc; 1990 Aug; 22(4):1753-4. PubMed ID: 2117798
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
    Shield CF
    Clin Transpl; 1990; ():265-74. PubMed ID: 2129408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy.
    Hirsch RL; Layton PC; Barnes LA; Kremer AB; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):32-6. PubMed ID: 3105138
    [No Abstract]   [Full Text] [Related]  

  • 8. Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantation: use of high doses of the new monoclonal antibody BMA 031.
    Dendorfer U; Hillebrand G; Kasper C; Smely S; Weschka M; Hammer C; Racenberg J; Gurland HJ; Land W
    Transplant Proc; 1990 Aug; 22(4):1789-90. PubMed ID: 2389450
    [No Abstract]   [Full Text] [Related]  

  • 9. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients.
    McDiarmid SV; Millis M; Terashita G; Ament ME; Busuttil R; Terasaki P
    Transplant Proc; 1990 Aug; 22(4):1774-6. PubMed ID: 2117806
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA; Mayes JT; Hricik DE
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation.
    Kahana L; Ackermann J; Lefor W; Weinstein S; Wright C; DeQuesada A; Alveranga D; Baxter J; Shires D
    Transplant Proc; 1990 Aug; 22(4):1755-8. PubMed ID: 2117799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadruple-drug induction therapy in combined renal and pancreatic transplantation--OKT3 versus ATG.
    Illner WD; Theodorakis J; Abendroth D; Schleibner S; Stangl M; Landgraf R; Land W
    Transplant Proc; 1990 Aug; 22(4):1586-7. PubMed ID: 2117795
    [No Abstract]   [Full Text] [Related]  

  • 13. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
    Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J
    Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797
    [No Abstract]   [Full Text] [Related]  

  • 14. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children.
    Woodle ES; Thistlethwaite JR; Emond JC; Whitington PF; Black DD; Aran PP; Baker AL; Stuart FP; Broelsch CE
    Transplant Proc; 1990 Aug; 22(4):1765-6. PubMed ID: 2117803
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 17. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF; Hughes JD
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthoclone OKT3 as rescue treatment for steroid-resistant and recurrent acute rejection in clinical renal transplantation.
    Tvedegaard E; Olgaard K
    Transplant Proc; 1990 Feb; 22(1):217-8. PubMed ID: 2106738
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
    Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
    Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.